中国医学创新Issue(13)：23-24,2.DOI:10.3969/j.issn.1674-4985.2013.13.011
多巴胺受体激动剂对帕金森综合征的疗效分析
Efficacy of Dopamine Agonists for Parkinson’s Syndrome
李吉顺1
作者信息
- 1. 辽宁省丹东市人民医院 辽宁 丹东 118000
- 折叠
摘要
Abstract
Objective:To investigate the dopamine receptor agonist pramipexole for Parkinson’s syndrome,in different periods,clinical efficacy and safety. Method:108 cases of Parkinson’s syndrome patients were randomly divided into pramipexole group and US-dopa group,and were given pramipexole and US-dopa therapy. Before treatment and 4 weeks,8 weeks after the occurrence of Parkinson’s Rating Scale theⅢpart(UPDRSⅢ)to respectively evaluate the clinical efficacy of the two groups,and to observe the adverse reactions of the two groups,UPDRSⅢscore 4 weeks of treatment. Result:There were no significant differences(P>0.05),and pramipexole group after eight weeks of treatment in patients with advanced UPDRS Ⅲscore was significantly lower than that of the Madopar group(P<0.05). The pramipexole adverse occurrence rate was significantly lower than that of the US-dopa(P<0.05). Conclusion:For the less effective Madopa advanced Parkinson’s syndrome patients,dopamine receptor agonists to achieve good efficacy and high safety,is worthy of clinical application.关键词
多巴胺受体激动剂/普拉克索/美多巴Key words
Dopamine agonists/Pramipexole/Madopar引用本文复制引用
李吉顺..多巴胺受体激动剂对帕金森综合征的疗效分析[J].中国医学创新,2013,(13):23-24,2.
